Compass expecting to report data from its Phase IIb study by the end of 2021. Cash on hand decreases to $190.3 million, from $196.5 million the previous quarter.
Psychedelics
Numinus to expand state-of-the-art psychedelics research laboratory
Numinus expands its research lab, including more research space, supply capacity and accelerated IP development.
Red-Hot Sale On Psychedelic Stocks
The psychedelic drug industry continues to advance by leaps-and-bounds. But psychedelic drug stocks are well off recent highs. The sale is on!
Previous antidepressant use may blunt the effectiveness of MDMA-assisted psychotherapy for PTSD
New research suggests that MDMA-assisted therapy for the treatment of posttraumatic stress disorder (PTSD) is less effective among those who have recently used selective serotonin reuptake inhibitors (SSRIs), a common psychiatric medication.
MindMed Announces C$19.5 Million Bought Deal Private Placement Offering
MindMed raises CAD$19.5 million selling units at CAD$3.25.
Local Activists In Washington State Push For Psilocybin Decriminalization
Voters in Spokane, Washington could make the city one of the latest to decriminalize psilocybin mushrooms under a proposed ordinance that was recently filed by local activists.
The Race to Patent Psychedelics Is Just Getting Started
The author and podcast host Tim Ferriss has done his share of heavy lifting when it comes to supporting and promoting research on psychedelic drugs.
Other Psychedelic Stocks Get Cheaper As atai Gets More Expensive
If atai Life Sciences trades in the expected manner off its IPO, its market cap will quickly exceed the COMBINED market caps of all other psychedelic stocks.
MINDCURE Discovers Potential Opportunity for Ibogaine-Assisted Psychotherapy to Treat Neuropathic Pain and Traumatic Brain Injury
This potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage
MagicMed Industries Announces Collaboration with Artificial Intelligence Thought Leaders and the Launch of PsyAI™
MagicMed Industries announces an R&D partnership for the development of PsyAI(TM), a an AI-based tool to "modernize psychedelic medicine."
atai Life Sciences Announces the Closing of its $157 Million Series D Financing Round
ATAI announces closing its Series D financing round, raising $157 million.
MINDCURE (CSE: MCUR | OTCQB: MCURF) Announces Manufacturing of Synthetic Ibogaine to be Used in Company's Clinical Research
The Company expects to have ibogaine manufactured and in use for research by Q4.
Iowa Lawmakers Hold Historic Hearing On Psilocybin Decriminalization, But Do Not Advance Bill
In a first-of-its kind hearing, an Iowa House panel on Wednesday took up a bill to decriminalize psilocybin mushrooms in the state.
MINDCURE (CSE: MCUR | OTCQB MCURF) Completes Its Initial Strategic Equity Investment in ATMA, Canada’s First Commercial Provider of Legal, Psychedelic-Assisted, Therapy Utilizing Psilocybin
The completed equity investment strengthens ties between MINDCURE and ATMA
First-of-its-kind trial finds psychedelic microdosing is equal to placebo
A first of its kind "self-blinded" trial testing the effect of psychedelic microdosing has found the anecdotally popular practice may be an example of a strong placebo effect.